Résultats: 8

    Latent TB infection: updated and consolidated guidelines for programmatic management

    Background The programmatic management of latent tuberculosis infection (LTBI) in populations most at risk of developing TB remains a critical activity to disrupt Mycobacterium tuberculosis transmission, as identified in the End TB Strategy. LTBI is defined as a state of persistent immune response to sti...

    Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update

    The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...

    Guidelines on the Management of Latent Tuberculosis Infection

    The overall objective of the guidelines is to provide public health approach guidance on evidencebased practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. The guidelines are expected to provide the basis and rationale for the developmen...

    Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB and HIV-prevalence settings: 2015 update

    In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...

    Guidance for national tuberculosis programmes on the management of tuberculosis in children

    This Guideline outlines the purpose and the target audience of the second edition of Guidance for national tuberculosis programmes on the management of tuberculosis in children. It discusses the difference between TB in children and adolescents and TB in adults and provides an estimate of the burden of c...

    Guidelines for the programmatic management of drug-resistant tuberculosis – 2011 update

    This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly’s resolution on prevention and control of multidrug-resistant tuberculosis and extensi...

    Treatment of tuberculosis: guidelines, 4th edition

    This is fourth edition of Treatment of tuberculosis: guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE...

    Management of MDR-TB: a field guide: a companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (‎IMAI)‎

    Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) increasingly occur in resource-constrained settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centres) will need t...